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Abstract 
Background: Follicular dendritic cell sarcoma is a rare tumour with clinical behaviour covering a spectrum from 
indolent to aggressive disease. Treatment recommendations are currently based on case reports and small series 
describing combinations of surgery, chemotherapy and radiotherapy providing the best patient outcomes. Recent 
knowledge on molecular aberrations in this disease have not yet impacted on therapeutic decisions.
Case presentation: We describe a case of progressive follicular dendritic cell sarcoma of the lung and pleura, treated 
based on knowledge of the tumour’s molecular aberrations. The patient was initially treated with surgery, chemo-
therapy and radiotherapy and developed disease progression. Mutation testing by Caris molecular intelligence 
demonstrated a breast cancer 2 gene mutation and further treatment with carboplatin and veliparib achieved disease 
stabilisation.
Conclusion: Understanding of the molecular profile of rare tumours is key to improve therapeutic decision making 
and patient outcomes.
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Background
Follicular dendritic cell sarcoma (FDCS) is an uncommon 
neoplasm of mesenchymal stem cell origin whose clinical 
course displays much variability. It was first described in 
1986 by Monda et al. [1] and was since classified in the 
2008 World Health Organization classification of haema-
tolymphoid neoplasms with tumours of histiocytes and 
dendritic cells, alongside other dendritic cell tumours 
including Langerhans cell tumours, interdigitating den-
dritic cell sarcoma and other rare tumours. Follicular 
dendritic cells (FDC) form a tight meshwork in primary 
and secondary lymphoid follicles and interact with T and 
B lymphocytes through antigen presentation and genera-
tion and regulation of the germinal centre reaction [2, 3].
FDCS was thought to be an indolent disease and in 
some patients with localized tumours, prognosis can be 
favourable with 2  year mortality only 3  % [4]. However 
some patients have a more aggressive tumour with local 
recurrence occurring in up to 43 %, distant metastases in 
21–24 % and disease-related mortality in 13–17 % [5–7]. 
A surveillance, epidemiology and end results (SEER) 
analysis of 54 patients reported a median overall survival 
of 48  months for those with distant disease [8]. FDCS 
most commonly presents as nodal disease though extran-
odal disease is reported in 33–46 % of patients and can 
involve the bowel, oropharynx, liver, spleen, pancreas, 
peritoneum, pleura, lung and thyroid [2, 9, 10].
Diagnosis is based on morphological and particularly 
immunohistochemical appearance with one or more of 
the following being positive: CD21, CD23, CD35, podo-
planin and CXCL-13 [5, 11, 12]. Other FDC markers such 
as R4/23, Ki-M4, Ki-M4p, Ki-FDC1 may also be positive 
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as well as vimentin, CD68, S100, fascin but these may be 
nonspecific. Typically, neoplastic cells lack CD1a, desmin 
and CD45 staining. Between 18.6 and 58  % have been 
reported as misdiagnosed at initial diagnosis, particu-
larly as the histological appearance may resemble other 
tumours and FDC markers are not always routine in 
immunohistochemical analysis [4, 5, 10].
Surgical excision is the standard minimum treat-
ment and intraabdominal tumours and those with other 
adverse histologic factors should be considered for adju-
vant treatment. Overall, better outcomes are reported in 
those patients whose initial treatment includes a com-
bination of surgery, chemotherapy and radiation where 
appropriate [5, 6]. Chemotherapy regimens that have 
documented responses include lymphoma protocols with 
cyclophosphamide, doxorubicin, vincristine and pred-
nisone (CHOP) and rituximab with CHOP (R-CHOP) as 
well as sarcoma protocols of doxorubicin and ifosfamide 
or gemcitabine and a taxane [6].
Due to its rare presentation, molecular analysis has 
been limited until more recently. Go et  al. [13] have 
reported v-Raf murine sarcoma viral oncogene homolog 
B (BRAF)V600E mutations in 5 from 27 (18.5  %) cases 
tested. Phosphatase and tension homolog (PTEN), RET 
and TP53 mutations have also been documented in FDCS 
presenting as a thyroid mass [10]. The PTEN and TP53 
mutations were similar to those previously described in 
other malignancies, though the functional significance 
of the RET mutation was unknown. Griffin et  al. [14] 
have now performed targeted genomic sequencing of 
309 known cancer-associated genes in 13 cases of FDCS 
and found recurrent alterations in nuclear factor (NF)-κB 
regulatory genes. However, none of these findings have 
as yet translated into use or trials of molecularly targeted 
therapies and research in this regard is of course limited 
by its rarity.
We report the first case using molecularly targeted 
therapy in combination with chemotherapy in a case of 
FDCS.
Case presentation
The patient is a 73 year old Caucasian lady who presented 
in November 2013 with a hoarse voice. She had a past 
history of a left total knee replacement, cholecycstectomy 
and appendecectomy and was on no regular medications. 
She had a 40 pack year smoking history. There were no 
significant findings on physical examination, notably no 
palpable lymphadenopathy, chest nor abdominal find-
ings. CT and FDG-PET imaging demonstrated lesions 
adjacent to the thoracic aortic arch, aortopulmonary lym-
phadenopathy, a left superior internal mammary lymph 
node and a left pleural/para-vertebral lesion near T10. 
An endobronchial ultrasound (EBUS) guided FNA biopsy 
of a subcarinal lymph node showed aggregates of epithe-
lioid histiocytes consistent with granulomas without evi-
dence of malignancy. Core biopsy was also attempted and 
showed abnormal lymphoid cells but without monoclo-
nality. In January 2014, the mediastinal mass, mediastinal 
lymph node and left pleural mass were resected via a left 
lateral thoracotomy and talc pleurodesis was performed 
to debulk the disease and obtain tissue for diagnosis. A 
timeline of the patient’s clinical course is outlined in 
Table 1.
The histopathological and immunohistochemical anal-
ysis led to a diagnosis of FDCS though the specimen was 
difficult to interpret due to admixed reactive popula-
tions of lymphocytes, fibroblasts, histiocytes and blood 
vessels. Focally, the tumour expressed some histiocytic 
and muscle markers, raising the possibility of inflam-
matory myofibroblastic sarcoma or histiocytic sarcoma 
but there were areas of bland spindle cells expressing 
CD21 favouring the diagnosis of FDCS. Interestingly, 
the tumour was positive for CD21 but negative for CD23 
and CD35. Subsequent FDG-PET scan showed residual 
mediastinal disease, a new T9 metastasis, and pleural-
based uptake thought to be secondary to pleurodesis. The 
case was reviewed at a multidisciplinary team meeting 
and treatment with CHOP chemotherapy, plus or minus 
radiotherapy, was recommended. She completed 4 cycles 
of CHOP and proceeded to mediastinal radiotherapy 
50.4 Gy in 28 fractions, encompassing all sites of disease 
and completed in July 2014.
At the same time, mutation testing with Caris Molec-
ular Intelligence was performed. This is a commercially 
available platform that identifies a spectrum of clini-
cally actionable treatment options based on immuno-
histochemistry (IHC), chromogenic and fluorescence 
in  situ hybridization (CISH/FISH), 46- and 592-gene 
Table 1 Patient’s clinical course
November 2013 January 2014 February–April 2014 April 2014 June–July 2014
Presented with hoarse voice Tumour resection and diagnosis of FDCS CHOP chemotherapy BRCA2 mutation detected Mediastinal radiotherapy
April 2015 June 2015 July–October 2015 October 2015 February 2016
Disease recurrence Carboplatin chemotherapy Concurrent veliparib with carboplatin Maintenance veliparib Stable at last follow-up
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next-generation sequencing (NGS), Sanger sequencing, 
pyrosequencing and fragment analysis, coupled with a 
literature review to correlate biomarkers with treatment 
response. An E1493  fs BRCA2 mutation was demon-
strated and confirmed as a germline mutation. Further 
family history detailed that her daughter had triple nega-
tive breast cancer at age 48  years, a maternal aunt died 
of postmenopausal breast cancer and this aunt’s own 
daughter also died of postmenopausal breast cancer. 
She has paternal German ancestry but no known Jewish 
ancestry. A hereditary genetics clinic was consulted and 
risk reducing surgery as well as family counselling was 
offered.
Follow-up PET in October 2014 demonstrated 
increased uptake in the left upper and lower lobes and 
increased intensity in pleural based disease. These 
changes were thought to be either treatment related or 
disease progression, with a further PET in February 2015 
confirming the latter.
Due to the finding of a BRCA2 mutation, it was decided 
to treat with the combination of carboplatin and a poly 
ADP-ribose polymerase (PARP) inhibitor. A compas-
sionate supply of veliparib was sought. Single agent car-
boplatin was given for 2 cycles in June 2015 with the 
introduction of veliparib 100  mg twice daily at the 3rd 
cycle in July 2015. FDG-PET scan after the 4th cycle 
showed reduced PET activity in the previously identi-
fied lesions. She completed 6 cycles of carboplatin with 
concurrent veliparib, followed by maintenance veliparib 
at 300  mg twice daily from October 2015. Her disease 
remains clinically stable after 5  months of veliparib 
monotherapy.
Interestingly, when excision repair cross-complemen-
tation group 1 (ERCC1) IHC was performed retrospec-
tively, it was negative, consistent with the benefit derived 
from carboplatin.
Conclusions
FDCS is a rare tumour with a spectrum of clinical behav-
iour. While some reports describe an indolent disease 
[4], others report higher rates of recurrence, metastases 
and mortality [5, 7]. There are a number of pathological 
features associated with a poorer prognosis, including 
size  ≥6  cm, coagulative necrosis, high mitotic counts 
(≥5 per 10 high power field), significant cytologic atypia, 
younger age and abdominal involvement [5, 6, 15]. As 
molecular information becomes more readily available 
for this tumour type, it will also be important to deter-
mine its correlation with natural history and therapeutic 
significance.
This case report describes the use of a PARP inhibi-
tor in combination with carboplatin in the treatment of 
a FDCS with a BRCA2 mutation. This is the first report 
of FDCS with a BRCA2 mutation and also the first report 
of the use of molecularly targeted therapy in this disease. 
BRCA2 is a tumour suppressor gene involved in deoxy-
ribonucleic (DNA) repair via homologous recombina-
tion [16]. Female carriers of a mutation have a 45 and 
20  % lifetime risk of breast cancer and ovarian cancer 
respectively [17]. BRCA2 mutation is also associated 
with prostate and pancreatic cancers and melanoma [17]. 
PARP inhibition in patients with a BRCA mutation dem-
onstrates the concept of synthetic lethality [18]. PARP1 
is a DNA repair enzyme that repairs DNA single strand 
breaks. Thus in cancer cells with BRCA2 mutation that 
already display a deficiency in DNA repair, inhibition of 
PARP1 activity leads to an accumulation of single strand 
breaks that are converted to double strand breaks that 
can not be repaired and result in cell death. Veliparib is 
a small molecular inhibitor of PARP 1 and PARP2 [19] 
with some activity, though less than olaparib, in so-
called PARP trapping, whereby complexes are formed 
with PARP1 and PARP2 that are also toxic to the cell 
[20]. There is also preclinical evidence that it potentiates 
the activity of cisplatin, carboplatin, temozolomide and 
cyclophosphamide [19, 21]. Veliparib has demonstrated 
activity in phase I and II studies in BRCA 1/2 mutated 
ovarian [22] and breast cancers [23] both as a single agent 
and in combination with carboplatin [24, 25] as well as 
in patients with brain metastases in combination with 
whole brain irradiation [26]. In this FDCS case, activity is 
seen both in the setting of a BRCA2 mutation as well as 
activity in combination with carboplatin.
The finding of ERCC1 IHC negativity is also of interest 
here. Although measured in retrospect, it supported the 
use of a platinum agent as opposed to further lymphoma 
or sarcoma protocols such as doxorubicin/ifosfamide or 
gemcitabine/taxane. ERCC1 is a DNA excision repair 
protein that recognizes and removes cisplatin-induced 
DNA adducts such that patients with ERCC1-negative 
tumours derive greater benefit from platinum-based 
chemotherapy [27]. Thus, with the identification of both 
a BRCA2 mutation and ERCC1 negativity, this case 
clearly demonstrates the benefit of molecular profiling 
in optimising therapy for this rare tumour and avoiding 
aggressive protocols from which the patient was unlikely 
to derive benefit.
The study of rare tumours, knowledge on their molecu-
lar aberrations and research into therapeutic strategies 
has been an area of need and is a particular challenge. 
Interestingly, as genomic alterations across cancer types 
are described through data repositories such as the Inter-
national Cancer Genome Consortium, Cancer Genome 
Project and Cancer Genome Atlas, classification of can-
cer based on molecular aberrations has gained traction 
with the molecular signature of some tumours guiding 
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therapeutic decisions rather than the histological sub-
type. In such a landscape, the challenge lies in attaining 
evidence for rare tumours to be treated in this man-
ner and novel trial design in this area is key. Alterna-
tive strategies such as basket and umbrella studies and 
Bayesian designs may assist in maximising recruitment 
and gaining useful information from a smaller sample 
size. Collaboration with the pharmaceutical industry is 
also required to gain access to drugs that may have been 
tested in one tumour type but may apply to rarer cancers 
with similar genetic aberrations.
This case highlights the importance of molecular pro-
filing across rare tumours both to better understand their 
biology and provide insight into potential therapeutic 
strategies. Well-designed multicentre clinical trials in 
this area with the collaboration of clinicians, research-
ers, statisticians and pharma is required to provide better 
outcomes for this patient group.
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